Skip to main content
Top
Published in: Supportive Care in Cancer 6/2012

01-06-2012 | Original Article

Recurrent brain tumour: the impact of illness on patient's life

Authors: Elena Lamperti, Giuseppe Pantaleo, Claudia Yvonne Finocchiaro, Antonio Silvani, Andrea Botturi, Paola Gaviani, Lucio Sarno, Andrea Salmaggi

Published in: Supportive Care in Cancer | Issue 6/2012

Login to get access

Abstract

Purpose

Despite advances in therapies that offer improved survival rates, clinical course of brain tumours leads to a progressive functional deterioration in patients with modifications in their psychological reaction to the disease. Patients with brain tumours are rarely assessed for quality of life and psychological variables, and even fewer studies have assessed patients who have experienced a recurrence of brain tumours. Therefore, the aim of the present study is to investigate the patients with recurrent brain tumours and their reaction to the illness.

Method

We enrolled 81 patients with recurrent CNS tumours. Karnofsky Performance Status scale (KPS) was used to evaluate functional status of patients; the multidimensional aspect of quality of life was assessed through “Functional Assessment of Cancer Therapy-Brain” (FACT-Br), “Hospital Anxiety and Depression Scale” and “Psychological Distress Inventory”. These were all used as tests of psychological well-being.

Results

Distress and almost all mean FACT-Br subscale scores seemed to be significantly lower in patients, in comparison with normative data. Surprisingly, the emotional well-being mean score was significantly higher in our recurrence sample than in patients with brain tumours at first diagnosis. Anxiety seemed not to be influenced by a relapse diagnosis; instead, depression was higher and differed significantly from normative data. Low correlation between KPS and FACT-Br total and some sub-scores was found.

Conclusions

Apparent dissociation between patients' judgment on their quality of life (bad except for emotional) and their reported distress (low) is the most intriguing finding, suggesting highly preserved coping strategies in the emotional sphere, despite intact judgment and disease awareness.
Literature
2.
go back to reference Zulch KJ (1986) Brain tumors. Their biology and pathology, 3rd edn. Springer Verlag, Berlin Zulch KJ (1986) Brain tumors. Their biology and pathology, 3rd edn. Springer Verlag, Berlin
3.
go back to reference Stupp R, Dietrich PY, Ostermann Kraljevic S, Pica A, Maillard I, Maeder P, Meuli R, Janzer R, Pizzolato G, Miralbell R, Porchet F, Regli L, de Tribolet N, Mirimanoff RO, Leyvraz S (2002) Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide. J Clin Oncol 20:1375–1382PubMedCrossRef Stupp R, Dietrich PY, Ostermann Kraljevic S, Pica A, Maillard I, Maeder P, Meuli R, Janzer R, Pizzolato G, Miralbell R, Porchet F, Regli L, de Tribolet N, Mirimanoff RO, Leyvraz S (2002) Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide. J Clin Oncol 20:1375–1382PubMedCrossRef
4.
go back to reference Fine HA, Dear KB, Loeffler JS, Black PM, Canellos GP (1993) Meta-analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults. Cancer 71:2585–2597PubMedCrossRef Fine HA, Dear KB, Loeffler JS, Black PM, Canellos GP (1993) Meta-analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults. Cancer 71:2585–2597PubMedCrossRef
5.
go back to reference Filippini G, Falcone C, Boiardi A, Broggi G, Bruzzone MG, Caldiroli D, Farina R, Farinotti M, Fariselli L, Finocchiaro G, Giombini S, Pollo B, Savoiardo M, Solero CL, Valsecchi MG, Brain Cancer Register of the Fondazione IRCCS (Istituto Ricovero e Cura a Carattere Scientifico) Istituto Neurologico Carlo Besta (2008) Prognostic factors for survival in 676 consecutive patients with newly diagnosed primary glioblastoma. Neuro Oncol 10:79–87PubMedCrossRef Filippini G, Falcone C, Boiardi A, Broggi G, Bruzzone MG, Caldiroli D, Farina R, Farinotti M, Fariselli L, Finocchiaro G, Giombini S, Pollo B, Savoiardo M, Solero CL, Valsecchi MG, Brain Cancer Register of the Fondazione IRCCS (Istituto Ricovero e Cura a Carattere Scientifico) Istituto Neurologico Carlo Besta (2008) Prognostic factors for survival in 676 consecutive patients with newly diagnosed primary glioblastoma. Neuro Oncol 10:79–87PubMedCrossRef
6.
go back to reference Schiffer D (1993) Brain tumors: pathology and its biological correlates. Springer-Verlag, Berlin Schiffer D (1993) Brain tumors: pathology and its biological correlates. Springer-Verlag, Berlin
7.
go back to reference Mork SJ, Lindegaard KF, Halvorsen TB, Lehmann EH, Solgaard T, Hatlevoll R, Harvei S, Ganz J (1985) Oligodendroglioma: incidence and biological behavior in a defined population. J Neurosurg 63:881–889PubMedCrossRef Mork SJ, Lindegaard KF, Halvorsen TB, Lehmann EH, Solgaard T, Hatlevoll R, Harvei S, Ganz J (1985) Oligodendroglioma: incidence and biological behavior in a defined population. J Neurosurg 63:881–889PubMedCrossRef
8.
go back to reference Freeman C, Berg JW, Cutler SJ (1972) Occurrence and prognosis of extranodal lymphomas. Cancer 29:252–260PubMedCrossRef Freeman C, Berg JW, Cutler SJ (1972) Occurrence and prognosis of extranodal lymphomas. Cancer 29:252–260PubMedCrossRef
9.
go back to reference Salander P, Bergenheim T, Henriksson R (1996) The creation of protection and hope in patients with malignant brain tumours. Soc Sci Med 42:985–996PubMedCrossRef Salander P, Bergenheim T, Henriksson R (1996) The creation of protection and hope in patients with malignant brain tumours. Soc Sci Med 42:985–996PubMedCrossRef
10.
go back to reference Gupta T, Sarin R (2002) Poor-prognosis high-grade gliomas: evolving an evidence-based standard of care. Lancet Oncol 3:557–564PubMedCrossRef Gupta T, Sarin R (2002) Poor-prognosis high-grade gliomas: evolving an evidence-based standard of care. Lancet Oncol 3:557–564PubMedCrossRef
11.
go back to reference Giovagnoli AR, Tamburini M, Boiardi A (1996) Quality of life in brain tumor patients. J Neurooncol 30:71–80PubMedCrossRef Giovagnoli AR, Tamburini M, Boiardi A (1996) Quality of life in brain tumor patients. J Neurooncol 30:71–80PubMedCrossRef
12.
go back to reference Kleihues P, Cavenee WK (2000) World Health Organization classification of tumors, pathology and genetics of tumors of the nervous system. IARC press, Lyon Kleihues P, Cavenee WK (2000) World Health Organization classification of tumors, pathology and genetics of tumors of the nervous system. IARC press, Lyon
13.
go back to reference Folstein MF, Folstein SE, McHugh PR (1975) “Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12:189–198PubMedCrossRef Folstein MF, Folstein SE, McHugh PR (1975) “Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12:189–198PubMedCrossRef
14.
go back to reference Meyers CA, Wefel JS (2003) The use of the mini-mental state examination to assess cognitive functioning in cancer trials: no ifs, ands, buts, or sensitivity. J Clin Oncol 21:3557–3558PubMedCrossRef Meyers CA, Wefel JS (2003) The use of the mini-mental state examination to assess cognitive functioning in cancer trials: no ifs, ands, buts, or sensitivity. J Clin Oncol 21:3557–3558PubMedCrossRef
15.
go back to reference Conill C, Verger E, Salamero M (1990) Performance status assessment in cancer patients. Cancer 65:1864–1866PubMedCrossRef Conill C, Verger E, Salamero M (1990) Performance status assessment in cancer patients. Cancer 65:1864–1866PubMedCrossRef
16.
go back to reference Karnofsky DA, Burchenal JH (1949) The clinical evaluation of chemotherapeutic agents in cancer in evaluation of chemotherapeutic agents. In: MacLeod CM (ed) Evaluation of chemotherapeutic agents. Columbia University Press, New York, pp 191–205, or pp. 196 Karnofsky DA, Burchenal JH (1949) The clinical evaluation of chemotherapeutic agents in cancer in evaluation of chemotherapeutic agents. In: MacLeod CM (ed) Evaluation of chemotherapeutic agents. Columbia University Press, New York, pp 191–205, or pp. 196
17.
go back to reference Sachsenheimer W, Piotrowski W, Bimmler T (1992) Quality of life in patients with intracranial tumors on the basis of Karnofsky's performance status. J Neurooncol 13:177–181PubMedCrossRef Sachsenheimer W, Piotrowski W, Bimmler T (1992) Quality of life in patients with intracranial tumors on the basis of Karnofsky's performance status. J Neurooncol 13:177–181PubMedCrossRef
18.
go back to reference Weitzner MA, Meyers CA, Gelke CK, Byrne KS, Cella DF, Levin VA (1995) The Functional Assessment of Cancer Therapy (FACT) scale. Development of a brain subscale and revalidation of the general version (FACT-G) in patients with primary brain tumors. Cancer 75:1151–1161PubMedCrossRef Weitzner MA, Meyers CA, Gelke CK, Byrne KS, Cella DF, Levin VA (1995) The Functional Assessment of Cancer Therapy (FACT) scale. Development of a brain subscale and revalidation of the general version (FACT-G) in patients with primary brain tumors. Cancer 75:1151–1161PubMedCrossRef
19.
go back to reference Cella DF, Tulsky DS, Gray G, Sarafian B, Linn E, Bonomi A, Silberman M, Yellen SB, Winicour P, Brannon J (1993) The Functional Assessment of Cancer Therapy scale: development and validation of the general measure. J Clin Oncol 11:570–579PubMed Cella DF, Tulsky DS, Gray G, Sarafian B, Linn E, Bonomi A, Silberman M, Yellen SB, Winicour P, Brannon J (1993) The Functional Assessment of Cancer Therapy scale: development and validation of the general measure. J Clin Oncol 11:570–579PubMed
20.
go back to reference Costantini M, Musso M, Viterbori P, Bonci F, Del Mastro L, Garrone O, Venturini M, Morasso G (1999) Detecting psychological distress in cancer patients: validity of the Italian version of the Hospital Anxiety and Depression Scale. Support Care Cancer 7:121–127PubMedCrossRef Costantini M, Musso M, Viterbori P, Bonci F, Del Mastro L, Garrone O, Venturini M, Morasso G (1999) Detecting psychological distress in cancer patients: validity of the Italian version of the Hospital Anxiety and Depression Scale. Support Care Cancer 7:121–127PubMedCrossRef
21.
go back to reference Zigmond AS, Snaith RP (1983) The hospital anxiety and depression scale. Acta Psychiatr Scand 67:361–370PubMedCrossRef Zigmond AS, Snaith RP (1983) The hospital anxiety and depression scale. Acta Psychiatr Scand 67:361–370PubMedCrossRef
22.
go back to reference Hopwood P, Howell A, Maguire P (1991) Screening for psychiatric morbidity in patients with advanced breast cancer: validation of two self-report questionnaires. Br J Cancer 64:353–356PubMedCrossRef Hopwood P, Howell A, Maguire P (1991) Screening for psychiatric morbidity in patients with advanced breast cancer: validation of two self-report questionnaires. Br J Cancer 64:353–356PubMedCrossRef
23.
go back to reference Morasso G, Costantini M, Baracco G, Borreani C, Capelli M (1996) Assessing psychological distress in cancer patients: validation of a self-administered questionnaire. Oncology 53:295–302PubMedCrossRef Morasso G, Costantini M, Baracco G, Borreani C, Capelli M (1996) Assessing psychological distress in cancer patients: validation of a self-administered questionnaire. Oncology 53:295–302PubMedCrossRef
24.
go back to reference Holzner B, Kemmler G, Cella D, De Paoli C, Meraner V, Kopp M, Greil R, Fleischhacker WW, Sperner-Unterweger B (2004) Normative data for functional assessment of cancer therapy—general scale and its use for the interpretation of quality of life scores in cancer survivors. Acta Oncol 43:153–160PubMedCrossRef Holzner B, Kemmler G, Cella D, De Paoli C, Meraner V, Kopp M, Greil R, Fleischhacker WW, Sperner-Unterweger B (2004) Normative data for functional assessment of cancer therapy—general scale and its use for the interpretation of quality of life scores in cancer survivors. Acta Oncol 43:153–160PubMedCrossRef
25.
go back to reference Crawford JR, Henry JD, Crombie C, Taylor EP (2001) Normative data for the HADS from a large non-clinical sample. Br J Clin Psychol 40:429–434PubMedCrossRef Crawford JR, Henry JD, Crombie C, Taylor EP (2001) Normative data for the HADS from a large non-clinical sample. Br J Clin Psychol 40:429–434PubMedCrossRef
26.
go back to reference Fox S (2004) Preliminary psychometric testing of the Fox Simple Quality-of-Life Scale. J Neurosci Nurs 36:157–166PubMedCrossRef Fox S (2004) Preliminary psychometric testing of the Fox Simple Quality-of-Life Scale. J Neurosci Nurs 36:157–166PubMedCrossRef
27.
go back to reference Pelletier G, Verhoef MJ, Khatri N, Hagen N (2002) Quality of life in brain tumor patients: the relative contributions of depression, fatigue, emotional distress, and existential issues. J Neurooncol 57:41–49PubMedCrossRef Pelletier G, Verhoef MJ, Khatri N, Hagen N (2002) Quality of life in brain tumor patients: the relative contributions of depression, fatigue, emotional distress, and existential issues. J Neurooncol 57:41–49PubMedCrossRef
28.
go back to reference Fox SW, Lyon D, Farace E (2007) Symptom clusters in patients with high-grade glioma. J Nurs Scholarsh 39:61–67PubMedCrossRef Fox SW, Lyon D, Farace E (2007) Symptom clusters in patients with high-grade glioma. J Nurs Scholarsh 39:61–67PubMedCrossRef
29.
go back to reference Litofsky NS, Farace E, Anderson F Jr, Meyers CA, Huang W, Laws ER Jr, Glioma Outcomes Project Investigators (2004) Depression in patients with high-grade glioma: results of the Glioma Outcomes Project. Neurosurgery 54:358–66, discussion 366–7PubMedCrossRef Litofsky NS, Farace E, Anderson F Jr, Meyers CA, Huang W, Laws ER Jr, Glioma Outcomes Project Investigators (2004) Depression in patients with high-grade glioma: results of the Glioma Outcomes Project. Neurosurgery 54:358–66, discussion 366–7PubMedCrossRef
30.
go back to reference Salander P, Bergenheim AT, Hamberg K, Henriksson R (1999) Pathways from symptoms to medical care: a descriptive study of symptom development and obstacles to early diagnosis in brain tumour patients. Fam Pract 16:143–148PubMedCrossRef Salander P, Bergenheim AT, Hamberg K, Henriksson R (1999) Pathways from symptoms to medical care: a descriptive study of symptom development and obstacles to early diagnosis in brain tumour patients. Fam Pract 16:143–148PubMedCrossRef
31.
go back to reference Pringle AM, Taylor R, Whittle IR (1999) Anxiety and depression in patients with an intracranial neoplasm before and after tumour surgery. Br J Neurosurg 13:46–51PubMedCrossRef Pringle AM, Taylor R, Whittle IR (1999) Anxiety and depression in patients with an intracranial neoplasm before and after tumour surgery. Br J Neurosurg 13:46–51PubMedCrossRef
32.
go back to reference Mainio A, Hakko H, Niemela A, Koivukangas J, Rasanen P (2005) Depression and functional outcome in patients with brain tumors: a population-based 1-year follow-up study. J Neurosurg 103:841–847PubMedCrossRef Mainio A, Hakko H, Niemela A, Koivukangas J, Rasanen P (2005) Depression and functional outcome in patients with brain tumors: a population-based 1-year follow-up study. J Neurosurg 103:841–847PubMedCrossRef
33.
go back to reference de Figueiredo JM (1993) Depression and demoralization: phenomenologic differences and research perspectives. Compr Psychiatry 34:308–311PubMedCrossRef de Figueiredo JM (1993) Depression and demoralization: phenomenologic differences and research perspectives. Compr Psychiatry 34:308–311PubMedCrossRef
34.
go back to reference Pace A, Pompili A (2005) Depression in patients with high-grade glioma: results of the Glioma Project. Neurosurgery 56:E629PubMedCrossRef Pace A, Pompili A (2005) Depression in patients with high-grade glioma: results of the Glioma Project. Neurosurgery 56:E629PubMedCrossRef
35.
go back to reference Kilbride L, Smith G, Grant R (2007) The frequency and cause of anxiety and depression amongst patients with malignant brain tumours between surgery and radiotherapy. J Neurooncol 84:297–304PubMedCrossRef Kilbride L, Smith G, Grant R (2007) The frequency and cause of anxiety and depression amongst patients with malignant brain tumours between surgery and radiotherapy. J Neurooncol 84:297–304PubMedCrossRef
36.
go back to reference Aben I, Verhey F, Lousberg R, Lodder J, Honig A (2002) Validity of the Beck Depression Inventory, Hospital Anxiety and Depression Scale, SCL-90, and Hamilton Depression Rating Scale as screening instruments for depression in stroke patients. Psychosomatics 43:386–393PubMedCrossRef Aben I, Verhey F, Lousberg R, Lodder J, Honig A (2002) Validity of the Beck Depression Inventory, Hospital Anxiety and Depression Scale, SCL-90, and Hamilton Depression Rating Scale as screening instruments for depression in stroke patients. Psychosomatics 43:386–393PubMedCrossRef
37.
go back to reference Meyers CA, Brown PD (2006) Role and relevance of neurocognitive assessment in clinical trials of patients with CNS tumors. J Clin Oncol 24:1305–1309PubMedCrossRef Meyers CA, Brown PD (2006) Role and relevance of neurocognitive assessment in clinical trials of patients with CNS tumors. J Clin Oncol 24:1305–1309PubMedCrossRef
38.
go back to reference Huang ME, Wartella JE, Kreutzer JS (2001) Functional outcomes and quality of life in patients with brain tumors: a preliminary report. Arch Phys Med Rehabil 82:1540–1546PubMedCrossRef Huang ME, Wartella JE, Kreutzer JS (2001) Functional outcomes and quality of life in patients with brain tumors: a preliminary report. Arch Phys Med Rehabil 82:1540–1546PubMedCrossRef
Metadata
Title
Recurrent brain tumour: the impact of illness on patient's life
Authors
Elena Lamperti
Giuseppe Pantaleo
Claudia Yvonne Finocchiaro
Antonio Silvani
Andrea Botturi
Paola Gaviani
Lucio Sarno
Andrea Salmaggi
Publication date
01-06-2012
Publisher
Springer-Verlag
Published in
Supportive Care in Cancer / Issue 6/2012
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-011-1220-y

Other articles of this Issue 6/2012

Supportive Care in Cancer 6/2012 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine